BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernández Fabrellas E, Peris Sánchez R, Sabater Abad C, Juan Samper G. Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis. Med Sci (Basel) 2018;6:E51. [PMID: 29904028 DOI: 10.3390/medsci6020051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Nishioka Y, Homma S, Okubo T, Azuma A. Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis. Contemp Clin Trials Commun 2021;23:100832. [PMID: 34471721 DOI: 10.1016/j.conctc.2021.100832] [Reference Citation Analysis]
2 Ruta VM, Man AM, Alexescu TG, Motoc NS, Tarmure S, Ungur RA, Todea DA, Coste SC, Valean D, Pop MC. Neutrophil-To-Lymphocyte Ratio and Systemic Immune-Inflammation Index-Biomarkers in Interstitial Lung Disease. Medicina (Kaunas) 2020;56:E381. [PMID: 32751302 DOI: 10.3390/medicina56080381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Ballester B, Milara J, Montero P, Cortijo J. MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway. Int J Mol Sci 2021;22:6502. [PMID: 34204432 DOI: 10.3390/ijms22126502] [Reference Citation Analysis]
4 Galioto F, Palmucci S, Astuti GM, Vancheri A, Distefano G, Tiralongo F, Libra A, Cusumano G, Basile A, Vancheri C. Complications in Idiopathic Pulmonary Fibrosis: Focus on Their Clinical and Radiological Features. Diagnostics (Basel) 2020;10:E450. [PMID: 32635390 DOI: 10.3390/diagnostics10070450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ballester B, Milara J, Cortijo J. Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation. Oncotarget 2020;11:1306-20. [PMID: 32341751 DOI: 10.18632/oncotarget.27526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Coskun F, Hanta I, Cilli A, Ozkaya G, Ursavas A, Sevinc C. Effects of the COVID-19 pandemic on the follow-up and treatment of patients with idiopathic pulmonary fibrosis: a cross-sectional, multicentre phone call survey. BMJ Open 2021;11:e050578. [PMID: 34385255 DOI: 10.1136/bmjopen-2021-050578] [Reference Citation Analysis]
7 Baddini-Martinez JA. Six-minute walk test in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 2018;44:257-8. [PMID: 30328922 DOI: 10.1590/S1806-37562018000040001] [Reference Citation Analysis]
8 Ballester B, Milara J, Cortijo J. Mucins as a New Frontier in Pulmonary Fibrosis. J Clin Med 2019;8:E1447. [PMID: 31514468 DOI: 10.3390/jcm8091447] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
9 Rai N, Baidya DK. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: Is Sequela the Bigger Threat? Indian J Crit Care Med 2021;25:245-6. [PMID: 33707913 DOI: 10.5005/jp-journals-10071-23734] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yang C, Chen C, Kuo Y, Ko C, Wu W, Liang C, Yun C, Huang W. Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study. Diagnostics 2022;12:1002. [DOI: 10.3390/diagnostics12041002] [Reference Citation Analysis]
11 Silveyra P, Fuentes N, Rodriguez Bauza DE. Sex and Gender Differences in Lung Disease. Adv Exp Med Biol 2021;1304:227-58. [PMID: 34019273 DOI: 10.1007/978-3-030-68748-9_14] [Cited by in F6Publishing: 1] [Reference Citation Analysis]